Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
J Pathol ; 250(2): 134-147, 2020 02.
Article in English | MEDLINE | ID: mdl-31518438

ABSTRACT

Colorectal cancer (CRC) is the fourth cause of death from cancer worldwide mainly due to the high incidence of drug-resistance. During a screen for new actionable targets in drug-resistant tumours we recently identified p65BTK - a novel oncogenic isoform of Bruton's tyrosine kinase. Studying three different cohorts of patients here we show that p65BTK expression correlates with histotype and cancer progression. Using drug-resistant TP53-null colon cancer cells as a model we demonstrated that p65BTK silencing or chemical inhibition overcame the 5-fluorouracil resistance of CRC cell lines and patient-derived organoids and significantly reduced the growth of xenografted tumours. Mechanistically, we show that blocking p65BTK in drug-resistant cells abolished a 5-FU-elicited TGFB1 protective response and triggered E2F-dependent apoptosis. Taken together, our data demonstrated that targeting p65BTK restores the apoptotic response to chemotherapy of drug-resistant CRCs and gives a proof-of-concept for suggesting the use of BTK inhibitors in combination with 5-FU as a novel therapeutic approach in CRC patients. © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Colonic Neoplasms/drug therapy , Protein Kinase Inhibitors/administration & dosage , Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors , Agammaglobulinaemia Tyrosine Kinase/metabolism , Animals , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Apoptosis/drug effects , Colonic Neoplasms/genetics , Colonic Neoplasms/pathology , Disease Progression , Drug Resistance, Neoplasm/drug effects , Drug Synergism , E2F Transcription Factors/metabolism , Fluorouracil/administration & dosage , Fluorouracil/pharmacology , Genes, p53 , Humans , Mice, Nude , Molecular Targeted Therapy/methods , Neoplasm Staging , Organoids/drug effects , Protein Isoforms/antagonists & inhibitors , Protein Isoforms/metabolism , Protein Kinase Inhibitors/pharmacology , Transforming Growth Factor beta1/metabolism , Tumor Cells, Cultured , Xenograft Model Antitumor Assays/methods
2.
J Exp Clin Cancer Res ; 38(1): 260, 2019 Jun 14.
Article in English | MEDLINE | ID: mdl-31200752

ABSTRACT

BACKGROUND: Lung cancer is still the main cause of cancer death worldwide despite the availability of targeted therapies and immune-checkpoint inhibitors combined with chemotherapy. Cancer cell heterogeneity and primary or acquired resistance mechanisms cause the elusive behaviour of this cancer and new biomarkers and active drugs are urgently needed to overcome these limitations. p65BTK, a novel isoform of the Bruton Tyrosine Kinase may represent a new actionable target in non-small cell lung cancer (NSCLC). METHODS: p65BTK expression was evaluated by immunohistochemistry in 382 NSCLC patients with complete clinico-pathological records including smoking habit, ALK and EGFR status, and in metastatic lymph nodes of 30 NSCLC patients. NSCLC cell lines mutated for p53 and/or a component of the RAS/MAPK pathway and primary lung cancer-derived cells from Kras/Trp53 null mice were used as a preclinical model. The effects of p65BTK inhibition by BTK Tyrosine Kinase Inhibitors (TKIs) (Ibrutinib, AVL-292, RN486) and first-generation EGFR-TKIs (Gefitinib, Erlotinib) on cell viability were evaluated by MTT. The effects of BTK-TKIs on cell growth and clonogenicity were assessed by crystal violet and colony assays, respectively. Cell toxicity assays were performed to study the effect of the combination of non-toxic concentrations of BTK-TKIs with EGFR-TKIs and standard-of-care (SOC) chemotherapy (Cisplatin, Gemcitabine, Pemetrexed). RESULTS: p65BTK was significantly over-expressed in EGFR-wild type (wt) adenocarcinomas (AdC) from non-smoker patients and its expression was also preserved at the metastatic site. p65BTK was also over-expressed in cell lines mutated for KRAS or for a component of the RAS/MAPK pathway and in tumors from Kras/Trp53 null mice. BTK-TKIs were more effective than EGFR-TKIs in decreasing cancer cell viability and significantly impaired cell proliferation and clonogenicity. Moreover, non-toxic doses of BTK-TKIs re-sensitized drug-resistant NSCLC cell lines to both target- and SOC therapy, independently from EGFR/KRAS status. CONCLUSIONS: p65BTK results as an emerging actionable target in non-smoking EGFR-wt AdC, also at advanced stages of disease. Notably, these patients are not eligible for EGFR-TKIs-based therapy due to a lack of EGFR mutation. The combination of BTK-TKIs with EGFR-TKIs is cytotoxic for EGFR-wt/KRAS-mutant/p53-null tumors and BTK-TKIs re-sensitizes drug-resistant NSCLC to SOC chemotherapy. Therefore, our data suggest that adding BTK-TKIs to SOC chemotherapy and EGFR-targeted therapy may open new avenues for clinical trials in currently untreatable NSCLC.


Subject(s)
Adenocarcinoma of Lung/genetics , Adenocarcinoma of Lung/metabolism , Agammaglobulinaemia Tyrosine Kinase/metabolism , Biomarkers, Tumor , Mutation , Proto-Oncogene Proteins p21(ras)/genetics , Adenocarcinoma of Lung/drug therapy , Adenocarcinoma of Lung/pathology , Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors , Agammaglobulinaemia Tyrosine Kinase/genetics , Animals , Antineoplastic Agents/pharmacology , Cell Line, Tumor , Cell Proliferation , Cell Survival/genetics , Drug Synergism , ErbB Receptors/genetics , Gene Expression , Gene Expression Regulation, Neoplastic , Humans , Immunohistochemistry , Mice , Neoplasm Staging , Protein Isoforms , Protein Kinase Inhibitors/pharmacology , Signal Transduction
3.
PLoS One ; 9(7): e100947, 2014.
Article in English | MEDLINE | ID: mdl-24984063

ABSTRACT

Glycogen Synthase Kinase-3 alpha (GSK3A) and beta (GSK3B) isoforms are encoded by distinct genes, are 98% identical within their kinase domain and perform similar functions in several settings; however, they are not completely redundant and, depending on the cell type and differentiative status, they also play unique roles. We recently identified a role for GSK3B in drug resistance by demonstrating that its inhibition enables necroptosis in response to chemotherapy in p53-null drug-resistant colon carcinoma cells. We report here that, similarly to GSK3B, also GSK3A silencing/inhibition does not affect cell proliferation or cell cycle but only abolishes growth after treatment with DNA-damaging chemotherapy. In particular, blocking GSK3A impairs DNA repair upon exposure to DNA-damaging drugs. As a consequence, p53-null cells overcome their inability to undergo apoptosis and mount a necroptotic response, characterized by absence of caspase activation and RIP1-independent, PARP-dependent AIF nuclear re-localization. We therefore conclude that GSK3A is redundant with GSK3B in regulating drug-resistance and chemotherapy-induced necroptosis and suggest that inhibition of only one isoform, or rather partial inhibition of overall cellular GSK3 activity, is enough to re-sensitize drug-resistant cells to chemotherapy.


Subject(s)
Apoptosis , Colonic Neoplasms/enzymology , Drug Resistance, Neoplasm , Glycogen Synthase Kinase 3/metabolism , Cell Line, Tumor , Colonic Neoplasms/drug therapy , Colonic Neoplasms/genetics , Colonic Neoplasms/pathology , Glycogen Synthase Kinase 3/genetics , Glycogen Synthase Kinase 3 beta , Humans , Isoenzymes/genetics , Isoenzymes/metabolism , Necrosis , Tumor Suppressor Protein p53/genetics
4.
Clin Cancer Res ; 19(14): 3820-31, 2013 Jul 15.
Article in English | MEDLINE | ID: mdl-23729362

ABSTRACT

PURPOSE: Evasion from chemotherapy-induced apoptosis due to p53 loss strongly contributes to drug resistance. Identification of specific targets for the treatment of drug-resistant p53-null tumors would therefore increase the effectiveness of cancer therapy. EXPERIMENTAL DESIGN: By using a kinase-directed short hairpin RNA library and HCT116p53KO drug-resistant colon carcinoma cells, glycogen synthase kinase 3 beta (GSK3B) was identified as a target whose silencing bypasses drug resistance due to loss of p53. p53-null colon cancer cell lines with different sets of mutations were used to validate the role of GSK3B in sustaining resistance and to characterize cell death mechanisms triggered by chemotherapy when GSK3B is silenced. In vivo xenograft studies were conducted to confirm resensitization of drug-resistant cells to chemotherapy upon GSK3 inhibition. Colon cancer samples from a cohort of 50 chemotherapy-treated stage II patients were analyzed for active GSK3B expression. RESULTS: Downregulation of GSK3B in various drug-resistant p53-null colon cancer cell lines abolished cell viability and colony growth after drug addition without affecting cell proliferation or cell cycle in untreated cells. Cell death of 5-fluorouracil (5FU)-treated p53-null GSK3B-silenced colon carcinoma cells occurred via PARP1-dependent and AIF-mediated but RIP1-independent necroptosis. In vivo studies showed that drug-resistant xenograft tumor mass was significantly reduced only when 5FU was given after GSK3B inhibition. Tissue microarray analysis of colon carcinoma samples from 5FU-treated patients revealed that GSK3B is significantly more activated in drug-resistant versus responsive patients. CONCLUSIONS: Targeting GSK3B, in combination with chemotherapy, may represent a novel strategy for the treatment of chemotherapy-resistant tumors.


Subject(s)
Antimetabolites, Antineoplastic/pharmacology , Colonic Neoplasms/enzymology , Drug Resistance, Neoplasm , Fluorouracil/pharmacology , Glycogen Synthase Kinase 3/metabolism , Tumor Suppressor Protein p53/genetics , Animals , Antimetabolites, Antineoplastic/therapeutic use , Apoptosis , Colonic Neoplasms/drug therapy , Colonic Neoplasms/mortality , DNA Damage , Drug Synergism , Enzyme Activation , Female , Fluorouracil/therapeutic use , Gene Knockdown Techniques , Glycogen Synthase Kinase 3/antagonists & inhibitors , Glycogen Synthase Kinase 3/genetics , Glycogen Synthase Kinase 3 beta , HCT116 Cells , Humans , Kaplan-Meier Estimate , Lithium Chloride/pharmacology , Lithium Chloride/therapeutic use , Mice , Mice, Nude , Necrosis , RNA, Small Interfering/genetics , Tumor Suppressor Protein p53/metabolism , Xenograft Model Antitumor Assays
5.
Epilepsia ; 47(3): 640-3, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16529633

ABSTRACT

PURPOSE: EPM2B mutations have been found in a variable proportion of patients with Lafora disease (LD). Genotype-phenotype correlations suggested that EPM2B patients show a slower course of the disease, with delayed age at death, compared with EPM2A patients. We herein report clinical and genetic findings of 26 Italian LD patients. METHODS: Disease progression was evaluated by means of a disability scale based on residual motor and cognitive functions and daily living and social abilities, at 4 years from the onset. Mutational analysis was performed by sequencing the coding regions of the EPM2A and EPM2B genes. RESULTS: Age at onset ranged from 8.5 to 18.5 years (mean, 13.7+/-2.6). The mean duration of follow-up was 7.1+/-3.9 years. Daily living activities and social interactions were preserved in five of 24 patients. The remaining patients showed moderate to extremely severe limitations of daily living and social abilities. Sixteen (72%) of 22 families showed mutations in the EPM2B gene, and five (22%), in the EPM2A gene. One family showed no mutations. A novel EPM2B mutation also was identified. CONCLUSIONS: In our series, EPM2B mutations occurred in 72% of families, thus indicating that EPM2B is the major gene for LD in the Italian population. Moreover, we found that six of 17 EPM2B patients preserved daily living activities and social interactions at 4 years from onset, suggesting a slow disease progression. Additional clinical and functional studies will clarify whether specific mutations may influence the course of the disease in LD patients.


Subject(s)
Carrier Proteins/genetics , Lafora Disease/diagnosis , Lafora Disease/genetics , Mutation/genetics , White People/genetics , Activities of Daily Living , Adolescent , Age of Onset , Child , Disability Evaluation , Disease Progression , Female , Follow-Up Studies , Gene Frequency/genetics , Genotype , Humans , Interpersonal Relations , Italy/ethnology , Lafora Disease/ethnology , Longitudinal Studies , Male , Pedigree , Phenotype , Ubiquitin-Protein Ligases
6.
Hum Mutat ; 26(4): 397, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16134145

ABSTRACT

Progressive Myoclonus Epilepsy (PME) of the Lafora type is an autosomal recessive disease, which presents in teenage years with myoclonia and generalized seizures leading to death within a decade of onset. It is characterized by pathognomonic inclusions, Lafora bodies (LB), in neurons and other cell types. Two genes causing Lafora disease (LD), EPM2A on chromosome 6q24 and NHLRC1 (EPM2B) on chromosome 6p22.3 have been identified, and our recent results indicate there is at least one other gene causing the disease. The EPM2A gene product, laforin, is a protein tyrosine phosphatase (PTP) with a carbohydrate-binding domain (CBD) in the N-terminus. NHLRC1 encodes a protein named malin, containing a zinc finger of the RING type in the N-terminal half and 6 NHL-repeat domains in the C-terminal direction. To date 43 different variations in EPM2A and 23 in NHLRC1 are known, including missense, nonsense, frameshift, and deletions. We have developed a human LD mutation database using a new generic biological database cross-referencing platform. The database, which currently contains 66 entries is accessible on the World Wide Web (http://projects.tcag.ca/lafora). Entries can be submitted via the curator of the database or via a web-based form.


Subject(s)
Carrier Proteins/genetics , Databases, Genetic , Mutation , Myoclonic Epilepsies, Progressive/genetics , Protein Tyrosine Phosphatases/genetics , Adolescent , Humans , Protein Tyrosine Phosphatases, Non-Receptor , Software , Ubiquitin-Protein Ligases
7.
Hum Mol Genet ; 14(18): 2727-36, 2005 Sep 15.
Article in English | MEDLINE | ID: mdl-16115820

ABSTRACT

Lafora progressive myoclonus epilepsy, caused by defective laforin or malin, insidiously present in normal teenagers with cognitive decline, followed by rapidly intractable epilepsy, dementia and death. Pathology reveals neurodegeneration with neurofibrillary tangle formation and Lafora bodies (LBs). LBs are deposits of starch-like polyglucosans, insufficiently branched and hence insoluble glycogen molecules resulting from glycogen synthase (GS) overactivity relative to glycogen branching enzyme activity. We previously made the unexpected observation that laforin, in the absence of which polyglucosans accumulate, specifically binds polyglucosans. This suggested that laforin's role is to detect polyglucosan appearances during glycogen synthesis and to initiate mechanisms to downregulate GS. Glycogen synthase kinase 3 (GSK3) is the principal inhibitor of GS. Dephosphorylation of GSK3 at Ser 9 activates GSK3 to inhibit GS through phosphorylation at multiple sites. Glucose-6-phosphate is a potent allosteric activator of GS. Glucose-6-phosphate levels are high when the amount of glucose increases and its activation of GS overrides any phospho-inhibition. Here, we show that laforin is a GSK3 Ser 9 phosphatase, and therefore capable of inactivating GS through GSK3. We also show that laforin interacts with malin and that malin is an E3 ubiquitin ligase that binds GS. We propose that laforin, in response to appearance of polyglucosans, directs two negative feedback pathways: polyglucosan-laforin-GSK3-GS to inhibit GS activity and polyglucosan-laforin-malin-GS to remove GS through proteasomal degradation.


Subject(s)
Carrier Proteins/metabolism , Glycogen Synthase Kinase 3/metabolism , Lafora Disease/metabolism , Protein Tyrosine Phosphatases/metabolism , Signal Transduction/physiology , Ubiquitin/metabolism , Glycogen Synthase/antagonists & inhibitors , Glycogen Synthase/metabolism , Humans , Immunohistochemistry , Immunoprecipitation , Microscopy, Electron , Muscle, Skeletal/metabolism , Muscle, Skeletal/ultrastructure , Protein Tyrosine Phosphatases, Non-Receptor , Two-Hybrid System Techniques , Ubiquitin-Protein Ligases
8.
Science ; 307(5706): 81, 2005 Jan 07.
Article in English | MEDLINE | ID: mdl-15637270

ABSTRACT

Epilepsy afflicts 1% of humans and 5% of dogs. We report a canine epilepsy mutation and evidence for the existence of repeat-expansion disease outside humans. A canid-specific unstable dodecamer repeat in the Epm2b (Nhlrc1) gene recurrently expands, causing a fatal epilepsy and contributing to the high incidence of canine epilepsy. Tracing the repeat origins revealed two successive events, starting 50 million years ago, unique to canid evolution. A genetic test, presented here, will allow carrier and presymptomatic diagnosis and disease eradication. Clinicopathologic characterization establishes affected animals as a model for Lafora disease, the most severe teenage-onset human epilepsy.


Subject(s)
DNA Repeat Expansion , Dog Diseases/genetics , Dogs/genetics , Lafora Disease/veterinary , Alleles , Animals , Chromosome Mapping , Cloning, Molecular , Female , Lafora Disease/genetics , Male , Muscle, Skeletal/metabolism , Pedigree , Polymerase Chain Reaction , RNA, Messenger/genetics , RNA, Messenger/metabolism , Sequence Analysis, DNA
9.
Hum Mol Genet ; 13(11): 1117-29, 2004 Jun 01.
Article in English | MEDLINE | ID: mdl-15102711

ABSTRACT

Lafora disease (LD) is a fatal and the most common form of adolescent-onset progressive epilepsy. Fulminant endoplasmic reticulum (ER)-associated depositions of starch-like long-stranded, poorly branched glycogen molecules [known as polyglucosans, which accumulate to form Lafora bodies (LBs)] are seen in neuronal perikarya and dendrites, liver, skeletal muscle and heart. The disease is caused by loss of function of the laforin dual-specificity phosphatase or the malin E3 ubiquitin ligase. Towards understanding the pathogenesis of polyglucosans in LD, we generated a transgenic mouse overexpressing inactivated laforin to trap normal laforin's unknown substrate. The trap was successful and LBs formed in liver, muscle, neuronal perikarya and dendrites. Using immunogold electron microscopy, we show that laforin is found in close proximity to the ER surrounding the polyglucosan accumulations. In neurons, it compartmentalizes to perikaryon and dendrites and not to axons. Importantly, it binds polyglucosans, establishing for the first time a direct association between the disease-defining storage product and disease protein. It preferentially binds polyglucosans over glycogen in vivo and starch over glycogen in vitro, suggesting that laforin's role begins after the appearance of polyglucosans and that the laforin pathway is involved in monitoring for and then preventing the formation of polyglucosans. In addition, we show that the laforin interacting protein, EPM2AIP1, also localizes on the polyglucosan masses, and we confirm laforin's intense binding to LBs in human LD biopsy material.


Subject(s)
Glucans/metabolism , Lafora Disease/pathology , Protein Tyrosine Phosphatases/metabolism , Actins/genetics , Animals , Brain/pathology , Dual-Specificity Phosphatases , Endoplasmic Reticulum/ultrastructure , Gene Transfer Techniques , Glycogen/metabolism , Humans , Immunochemistry , Inclusion Bodies/ultrastructure , Lafora Disease/genetics , Lafora Disease/metabolism , Liver/pathology , Mice , Mice, Transgenic , Promoter Regions, Genetic , Protein Binding , Protein Tyrosine Phosphatases/genetics , Protein Tyrosine Phosphatases, Non-Receptor , Proto-Oncogene Proteins c-myc/genetics , Proto-Oncogene Proteins c-myc/metabolism , Starch/metabolism
10.
Hum Mutat ; 23(2): 170-176, 2004 Feb.
Article in English | MEDLINE | ID: mdl-14722920

ABSTRACT

Lafora disease is the most severe teenage-onset progressive epilepsy, a unique form of glycogenosis with perikaryal accumulation of an abnormal form of glycogen, and a neurodegenerative disorder exhibiting an unusual generalized organellar disintegration. The disease is caused by mutations of the EPM2A gene, which encodes two isoforms of the laforin protein tyrosine phosphatase, having alternate carboxyl termini, one localized in the cytoplasm (endoplasmic reticulum) and the other in the nucleus. To date, all documented disease mutations, including the knockout mouse model deletion, have been in the segment of the protein common to both isoforms. It is therefore not known whether dysfunction of the cytoplasmic, nuclear, or both isoforms leads to the disease. In the present work, we identify six novel mutations, one of which, c.950insT (Q319fs), is the first mutation specific to the cytoplasmic laforin isoform, implicating this isoform in disease pathogenesis. To confirm this mutation's deleterious effect on laforin, we studied the resultant protein's subcellular localization and function and show a drastic reduction in its phosphatase activity, despite maintenance of its location at the endoplasmic reticulum.


Subject(s)
Cytoplasm/chemistry , Lafora Disease/genetics , Protein Tyrosine Phosphatases/deficiency , Protein Tyrosine Phosphatases/genetics , Adult , Amino Acid Sequence/genetics , Animals , Base Sequence/genetics , COS Cells , Cell Line , Chlorocebus aethiops , Cytoplasm/genetics , Dual-Specificity Phosphatases , Endoplasmic Reticulum/chemistry , Endoplasmic Reticulum/genetics , Female , Humans , Male , Mice , Mice, Knockout , Molecular Sequence Data , Mutation/genetics , Mutation, Missense/genetics , Pedigree , Protein Isoforms/deficiency , Protein Isoforms/genetics , Protein Isoforms/physiology , Protein Tyrosine Phosphatases/physiology , Protein Tyrosine Phosphatases, Non-Receptor
11.
Nat Genet ; 35(2): 125-7, 2003 Oct.
Article in English | MEDLINE | ID: mdl-12958597

ABSTRACT

Lafora progressive myoclonus epilepsy is characterized by pathognomonic endoplasmic reticulum (ER)-associated polyglucosan accumulations. We previously discovered that mutations in EPM2A cause Lafora disease. Here, we identify a second gene associated with this disease, NHLRC1 (also called EPM2B), which encodes malin, a putative E3 ubiquitin ligase with a RING finger domain and six NHL motifs. Laforin and malin colocalize to the ER, suggesting they operate in a related pathway protecting against polyglucosan accumulation and epilepsy.


Subject(s)
Carrier Proteins/genetics , Mutation , Myoclonic Epilepsies, Progressive/genetics , Protein Tyrosine Phosphatases/genetics , Base Sequence , Cohort Studies , Female , Homozygote , Humans , Lafora Disease/genetics , Male , Molecular Sequence Data , Myoclonic Epilepsies, Progressive/enzymology , Pedigree , Protein Tyrosine Phosphatases, Non-Receptor , Sequence Deletion , Ubiquitin-Protein Ligases
12.
Genomics ; 81(6): 579-87, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12782127

ABSTRACT

We have identified an interacting partner protein (encoded by the human EPM2AIP1 gene (approved symbol)) for laforin, the product of the EPM2A gene, which is mutated in an autosomal recessive form of adolescent progressive myoclonus epilepsy. The EPM2AIP1 gene was identified in a screen for laforin-interacting proteins with a human brain cDNA library using the yeast two-hybrid system. The specificity of the interaction was confirmed by coimmunoprecipitation of in vivo-transfected protein and by using EPM2A deletion constructs. Subcellular colocalization of laforin and EPM2AIP1 protein was also demonstrated. The human EPM2AIP1 gene, corresponding to the KIAA0766 cDNA clone in the databases, was characterized and shown, like EPM2A, to be ubiquitously expressed. The gene, which comprises one large exon 1824 nucleotides in length and has alternative 3' untranslated regions, maps to human chromosome 3p22.1. The function is currently not known and extensive analyses do not reveal any homology to other proteins or any obvious structural motifs. Because genetic heterogeneity in Lafora disease has been described, mutational analysis of the EPM2AIP1 gene was performed on non-EPM2A patients, but no mutations were found. The identification of this first binding partner for laforin promises to be an important step toward unraveling the underlying pathogenesis of this severest form of teenage-onset epilepsy.


Subject(s)
Carrier Proteins/metabolism , Protein Tyrosine Phosphatases/metabolism , Amino Acid Sequence , Brain , Carrier Proteins/genetics , Chromosomes, Human, Pair 3 , DNA Mutational Analysis , Gene Components , Gene Library , Humans , Lafora Disease/etiology , Lafora Disease/genetics , Molecular Sequence Data , Protein Binding , Protein Tyrosine Phosphatases, Non-Receptor , Two-Hybrid System Techniques
SELECTION OF CITATIONS
SEARCH DETAIL
...